These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17874490)

  • 1. Conjunctival hyperaemia and other ocular adverse effects on healthy African subjects after single dosing with 0.004% Travoprost.
    Ashaye AO; Adedapo AD; Olusanya BA; Adeoti CO
    Afr J Med Med Sci; 2007 Mar; 36(1):37-42. PubMed ID: 17874490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ocular surface side effects of topical travoprost and bimatoprost.
    Alagöz G; Bayer A; Boran C; Serin D; Kükner A; Elçioğlu M
    Ophthalmologica; 2008; 222(3):161-7. PubMed ID: 18497524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.
    Stewart WC; Kolker AE; Stewart JA; Leech J; Jackson AL
    Am J Ophthalmol; 2003 Mar; 135(3):314-20. PubMed ID: 12614748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
    Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
    J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.
    Trattler W; Noecker RJ; Earl ML
    Adv Ther; 2008 Mar; 25(3):179-89. PubMed ID: 18351298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
    Kahook MY; Noecker RJ
    Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased iridial pigmentation in Chinese eyes after use of travoprost 0.004%.
    Huang P; Zhong Z; Wu L; Liu W
    J Glaucoma; 2009 Feb; 18(2):153-6. PubMed ID: 19225354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma.
    Konstas AG; Mikropoulos D; Haidich AB; Ntampos KS; Stewart WC
    Br J Ophthalmol; 2009 Apr; 93(4):481-5. PubMed ID: 19019932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma.
    Konstas AG; Tsironi S; Vakalis AN; Nasr MB; Stewart JA; Nelson LA; Stewart WC
    Acta Ophthalmol; 2009 Feb; 87(1):71-6. PubMed ID: 19178390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of additional topical cyclosporine or vitamin A on the ocular surface during antiglaucoma medication administration.
    Cho HK; Park MH; Moon JI
    Ophthalmic Res; 2012; 48(3):139-45. PubMed ID: 22572974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
    Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
    Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
    Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
    J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma.
    Kumar RS; Istiantoro VW; Hoh ST; Ho CL; Oen FT; Aung T
    J Glaucoma; 2007; 16(7):606-9. PubMed ID: 18091178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time Course of Prostaglandin Analog-related Conjunctival Hyperemia and the Effect of a Nonsteroidal Anti-inflammatory Ophthalmic Solution.
    Sakata R; Sakisaka T; Matsuo H; Miyata K; Aihara M
    J Glaucoma; 2016 Mar; 25(3):e204-8. PubMed ID: 25642812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Periocular hyperpigmentation following travoprost application].
    Schmutz JL; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 2008; 135(6-7):537. PubMed ID: 18598816
    [No Abstract]   [Full Text] [Related]  

  • 20. Expansion of Schlemm's canal by travoprost in healthy subjects determined by Fourier-domain optical coherence tomography.
    Chen J; Huang H; Zhang S; Chen X; Sun X
    Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1127-34. PubMed ID: 23322574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.